The Use of Cannabinoids in Treating Dementia
Purpose of Review
To review and summarise the current evidence on the safety and efficacy of using cannabinoids to treat behavioural and neuropsychiatric symptoms of dementia.
Two randomised controlled trials testing a synthetic form of tetrahydrocannabinol have shown that while well tolerated, there was no significant therapeutic effect, based on changes to scores on the neuropsychiatric inventory (NPI). Case reports and open label trials have indicated that there may be some therapeutic benefit of adding synthetic cannabinoids as an adjunctive therapy to reduce agitation, aberrant motor behaviour and nighttime behaviour.
More well-controlled clinical trials in older populations with varying severity of dementia are needed to evaluate the effectiveness of cannabinoids in treating behaviour symptoms of dementia. We provide suggestions for designing such trials and evaluating possible adverse effects of cannabinoids on cognitive and neuropsychiatric functioning.
KeywordsCannabinoids Dementia Alzheimer’s disease Neuropsychiatric inventory Pharmacotherapies
Compliance with Ethical Standards
Conflict of Interest
Megan Weier receives payments from the Therapeutic Goods Administration to review the evidence on the efficacy and safety of cannabis and cannabinoids for medical use.
Wayne Hall receives payments from the Therapeutic Goods Administration to review the evidence on the efficacy and safety of cannabis and cannabinoids for medical use and is a member of the Australian Advisory Council on Medical Uses of Cannabis.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Eastwood R, Reisberg B. Mood and behaviour. In: Gauthier S, editor. Clinical diagnosis and management of Alzheimer’s disease. London: Martin Dunitz; 1996. p. 175–89.Google Scholar
- 4.Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Lib. 2006.Google Scholar
- 6.• Liu CS, Ruthirakuhan M, Chau SA, Herrmann N, Carvalho AF, Lanctot KL. Pharmacological management of agitation and aggression in Alzheimer’s disease: a review of current and novel treatments. Curr Alzheimer Res. 2016;13(10):1134–44. Reviews current pharmacological treatments for the management of Alzheimer’s disease, as well as updates on novel treatments. CrossRefPubMedGoogle Scholar
- 8.• Amanullah S, MacDougall K, Sweeney N, Coffin J, Cole J. Synthetic cannabinoids in dementia with agitation: case studies and literature review. Clin Neuropsychiatry. 2013;10(3-4):142–7. Case studies of patients who have benefitted from the addition of nabilone as an adjunctive treatment for agitation. Google Scholar
- 18.Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Lib. 2013.Google Scholar
- 22.Queensland Government. In: Health Do, editor. Clinical guidance for the use of medicinal cannabis products. Brisbane: Queensland Government; 2017. 32pp.Google Scholar
- 23.•• van den Elsen GA, Ahmed AI, Verkes R-J, Feuth T, van der Marck MA, Olde Rikkert MG. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am J Geriatr Psychiatry. 2015;23(12):1214–24. One of two available RCTs testing the efficacy of THC in dementia; van den Elsen et al. found that there was no significant benefit of THC in reducing behavioural disturbance; however, the therapy was well tolerated with no significant adverse events. CrossRefPubMedGoogle Scholar
- 24.•• van den Elsen GA, Ahmed AI, Verkes R-J, Kramers C, Feuth T, Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015;84(23):2338–46. One of two available RCTs testing the efficacy of THC in dementia; van den Elsen et al. found that there was no significant benefit of THC in improving NPI scores; however, the therapy was well tolerated with no significant adverse events. CrossRefPubMedPubMedCentralGoogle Scholar
- 25.• Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006;185(4):524–8. An open-label pilot study with six patients reported a reduction in nocturnal activity, as well as improvements in NPI scores, and no side effects were observed. CrossRefGoogle Scholar
- 26.• Shelef A, Barak Y, Berger U, Paleacu D, Tadger S, Plopsky I, et al. Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study. J Alzheimers Dis. 2016;51(1):15–9. An open-label add-on study of 11 patients with Alzheimer’s disease reported the addition of cannabis oil was safely integrated, with significant benefits to CGI and NPI scores. CrossRefPubMedGoogle Scholar
- 28.Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2009;2Google Scholar
- 29.Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ (Online). 2015;350 (no pagination)(h369).Google Scholar
- 32.Lonergan E, Luxenberg J, Colford JM, Birks J. Haloperidol for agitation in dementia. Cochrane Lib. 2002.Google Scholar
- 36.Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. The Cochrane Library. 2011.Google Scholar
- 49.New South Wales Government. Palliative care Sydney, NSW2017 [Available from: https://www.medicinalcannabis.nsw.gov.au/clinical-trials/terminal-illness-trial#main-content.].